Notice2022-10239
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Medical CBRN Defense Consortium
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 13, 2022
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 93 (Friday, May 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29383]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-10239]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Medical CBRN Defense Consortium
Notice is hereby given that, on April 7, 2022, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium
(``MCDC'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing changes in
its membership. The notifications were filed for the purpose of
extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, 7 Hills Pharma LLC, Houston, TX; Aleph Therapeutics,
Inc., Stanford, CA; Amaratek, San Diego, CA; Applied Research
Associates, Inc.; Albuquerque, NM; Horizons Global Solutions LLC;
Purcellville, VA; Icahn School of Medicine at Mount Sinai; New York,
NY; Iowa State University of Science and Technology; Ames, IA;
Mainstream Engineering Corporation; Rockledge, FL; Najit Technologies,
Inc.; Beaverton, OR; National Strategic Research Institute; Lincoln,
NE; POP Biotechnologies, Inc.; Buffalo, NY; The Henry M. Jackson
Foundation for the Advancement of Military Medicine; Bethesda, MD;
University of Massachusetts; Lowell, MA and Virion Therapeutics LLC;
Newark, DE have been added as parties to this venture.
Also, Aardvark Medical, Inc., Ross, CA; Cytonus Therapeutics, Inc.,
Columbus, OH; Entasis Therapeutics, Waltham, MA; EUSA Pharma (US) LLC,
Burlington, MA; GeneCapture, Inc., Huntsville, AL; and Visby Medical,
Inc., San Jose, CA, have withdrawn as parties to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and MCDC intends to file additional
written notifications disclosing all changes in membership.
On November 13, 2015, MCDC filed its original notification pursuant
to Section 6(a) of the Act. The Department of Justice published a
notice in the Federal Register pursuant to Section 6(b) of the Act on
January 6, 2016 (81 FR 513).
The last notification was filed with the Department on January 10,
2022. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on March 10, 2022 (87 FR 13756).
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10239 Filed 5-12-22; 8:45 am]
BILLING CODE P
</pre></body>
</html>Indexed from Federal Register on May 13, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.